P01-009 – 2 years of colchicine IV in intractable FMF by unknown
MEETING ABSTRACT Open Access
P01-009 – 2 years of colchicine IV in
intractable FMF
L Kaly*, N Boulman, D Rimar, G Slobodin, I Rosner, M Rozenbaum
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
Oral colchicine therapy has been shown effective both in
controlling the symptoms and preventing the development
of amyloidosis in FMF. However, 5 to 10% of FMF patients
are resistant to this conventional therapy.
Objectives
The objective of this study is to evaluate the efficacy and
safety of weekly intravenous colchicine (IVC) adjunct
therapy for more than one year.
Methods
We retrospectively reviewed records of our day-
hospitalization from 2007 to 2012 for patients with FMF
unresponsive to oral treatment who were treated with
supplemental 1mg IVC (120 min infusion) once a week.
We tabulated records of clinical events: fever, number of
attacks per month and CRP levels before and after at least
one year of this treatment. Adverse events were also
recorded, and compared with a matched control popula-
tion of FMF patients only treated with oral colchicine.
Results
Twelve patients were identified. Two with poor compli-
ance were excluded. Mean age was 39; 70% male. Mean
daily dose of oral colchicine was 2.1mg. Mean duration of
treatment with IVC was 2.1 years. The number of attacks
per month decreased by 68% (4 versus 1.3, before and
after respectively, p< 0.008). One patient exhibited an
adverse event: deep vein thrombosis of lower extremity.
Conclusion
Although IVC is a controversial option as treatment for
oral-colchicine- non-responsive FMF patients, our study
provides evidence of efficacy and relative safety for this
modality as long term treatment ,in young FMF patients
without comorbidities treated in an academic center,
experimented with the use of IVC.
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